| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
For the development of new strategy targeting on the interaction between hepatoceullar carcinoma (HCC) and hepatic stellate cells, we investigated the cross-talk ; namely angiotensin II (AngII)-a disintegrin and metalloprotease domain (ADAM)- epidermal growth factor receptor (EGFR). In both cell types (HCC and HSC), the increase of proliferation/invasion activities by the administration of Ang II was observed. The transactivation (AngII-ADAM-EGFR) was inhibited by angiotensin receptor blocker (ARB) and/or ADAM inhior (TAPI2). These results suggested ARB and/or ADAM inhibitor will be new drugs for the treatment in both HCC and liver fibrosis.
|
